Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Status:
Terminated
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard
of care therapies including a BTK inhibitor where one is approved for the indication.